EXTON, Pa., Dec. 18, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that Carol A. Schafer joined its Board of Directors, effective December 18, 2018.
Ms. Schafer is a seasoned financial professional with more than 25 years of experience in investment banking and equity capital markets, as well as corporate finance and business development in the biopharmaceutical sector. Ms. Schafer most recently served as Vice Chair, Equity Capital Markets at Wells Fargo Securities. Prior to Wells Fargo, Ms. Schafer served as Vice President of Finance and Business Development at Lexicon Pharmaceuticals. Earlier in her career, Ms. Schafer served as an Equity Capital Markets Sector Head in her role as a Managing Director at J.P. Morgan. Ms. Schafer received a B.A. from Boston College and an M.B.A from New York University.
“Carol brings a unique set of skills and experience that traverses the financial and corporate biotech landscape and will be incredibly valuable to our board as we continue to advance Idera’s mission to bring forward options for patients suffering from life-threatening diseases and ultimately create long-term shareholder value,” stated James Geraghty, Chairman of Idera’s Board of Directors.
Ms. Schafer will be succeeding Mr. William Reardon, who will be resigning from the Board effective March 10, 2019.
“We are extremely thankful for the contributions provided by Bill through his 16 years of service on the Board of Idera,” continued Mr. Geraghty. “We also appreciate Bill’s further dedication to remain in the role to enable continuity and assist the transition of the Audit Committee Chairperson role to Carol through the 2018 year-end financial filing period.”
About Idera Pharmaceuticals
Harnessing the approach of the earliest researchers in immunotherapy and the Company’s vast experience in developing proprietary immunology platforms, Idera’s lead development program is focused on priming the immune system to play a more powerful role in fighting cancer, ultimately increasing the number of people who can benefit from immunotherapy. Idera also continues to focus on the acquisition, development and ultimate commercialization of drug candidates for both oncology and rare disease indications characterized by small, well-defined patient populations with serious unmet needs. To learn more about Idera, visit www.iderapharma.com.
